ARS Pharma 10-Q: Q3 Revenue $37.7M, Net Loss Narrows to $35.6M, $138.4M Cash
SPRY is trading near its 52-week low of $2.59 (2.3% above the low).
Summary
ARS Pharma's Q3 10-Q shows revenue of $37.7M and a narrowed $35.6M net loss on sharply lower SG&A, with $138.4M in cash and investments and $125.0M of term debt outstanding.
Key Events · Earnings and Guidance · SPRY
-
Q3 Revenue $37.7M, Loss Narrows
Total revenue rose to $37.7M from $32.5M, including $33.4M of U.S. neffy product revenue; net loss fell to $35.6M, or $(0.36) per share, from $51.2M, or $(0.52).
-
SG&A Cut to $43.5M
Selling, general and administrative expense dropped to $43.5M from $74.8M a year ago, a $31.2M reduction driven mainly by $38.0M less marketing spend.
-
Cash $138.4M, Debt $125.0M
Cash, cash equivalents and short-term investments were $138.4M at September 30, 2026; gross term loans reached $125.0M after the $25.0M Term B draw on September 25, 2026.
-
Equity Turns to Deficit
Total stockholders' equity went from $114.258M at December 31, 2025 to a $(11.955)M deficit, with the accumulated deficit at $453.1M.
Analysis · SPRY · Life Sciences
The headline numbers were already out via the morning 8-K, but the 10-Q is where the balance sheet and the risks live. Revenue of $37.7M against $32.5M a year ago came with SG&A cut to $43.5M from $74.8M, so the quarterly net loss fell to $35.6M from $51.2M — the cost side of the breakeven-by-end-2027 story is actually moving. Against that, stockholders' equity has flipped to a $(11.955)M deficit, the company has drawn $125.0M of term debt at a rate of 5.50% plus SOFR (floored at 3.00%), and it expensed a $12.5M upfront license payment in the quarter. Cash of $138.4M is the runway number that matters. The legal file also thickened: a securities class action filed August 5, 2026 over the neffy insurance-coverage timeline, a TCPA fax class action, and Lupin's October 1, 2026 stipulation that its proposed generics meet six asserted patents — leaving validity as the fight.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRY was trading at $2.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $263.5M. The 52-week trading range was $2.59 to $13.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.